🔎 Trials Near Me

Utama › Penyakit Paru Interstisial › Kansas › Kansas City

Kajian klinikal Penyakit Paru Interstisial di Kansas City, KS

13 kajian untuk Penyakit Paru Interstisial sedang mencari peserta di lokasi dalam dan sekitar Kansas City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Mengambil pesertaFasa 3
  • University of Kansas Medical Center, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07540988

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Mengambil pesertaFasa 3
  • University of Kansas Medical Center, Kansas City
Umur 40 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07201922

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Mengambil pesertaFasa 3
  • USA002, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07179380

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Mengambil pesertaFasa 2
  • University of Kansas Medical Center, Kansas City
Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06968845

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Mengambil pesertaFasa 2
  • Clinical Research Site, Kansas City
Umur 18 hingga 85 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07333183

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Mengambil pesertaKajian pemerhatian
  • University of Kansas Medical Center, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06388421

Platform Clinical Study for Conquering Scleroderma

Mengambil pesertaFasa 2
  • University of Kansas School of Medicine, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Mengambil pesertaFasa 2/3
  • University of Kansas Medical Center, Kansas City
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06328777

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Mengambil pesertaFasa 2
  • The University of Kansas Medical Center Research Institute, Kansas City
Umur 18 hingga 80 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07175038

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Mengambil pesertaFasa 3
  • University of Kansas Medical Center, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05943535

Interstitial Lung Disease Research Unit Biobank

Mengambil pesertaKajian pemerhatian
  • The University of Kansas Medical Center, Kansas City
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jul 2026 · NCT05392881

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
  • University of Kansas Medical Center, Kansas City
Umur 3 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT04624490

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Mengambil pesertaKajian pemerhatian
  • University of Kansas, Kansas City
Umur 18 hingga 90 · Semua jantina · Dikemas kini 3 Mei 2024 · NCT06397677

Kajian Penyakit Paru Interstisial di bandar lain

Kajian lain di Kansas City

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.